MedTrace Logo

Study of REN-1654 in Patients With Sciatica Pain

NCT00107055 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to gain initial safety and efficacy data on the experimental agent REN-1654 in patients with pain that radiates down the leg(s), and is typical of sciatica (lumbosacral radiculopathy). These patients will usually have a herniated disc that is causing compression on the nerves coming out of the spinal column.

Conditions

  • Sciatica
  • Herniated Disc
  • Radiculopathy

Interventions

DRUG

REN-1654

Sponsors & Collaborators

  • Renovis

    lead INDUSTRY

Principal Investigators

  • Randall W Moreadith, MD, PhD · Chief Medical Officer, Renovis, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
ECT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Completion
2005-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00107055 on ClinicalTrials.gov